Clinical

In part 3 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed the payer perspective in the rise of genomics.

In part 2 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed how genomics have changed the cancer care landscape.

In the latest Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed designing genomic testing in cancer care.

A new study says that treating iron deficiency therapy may improve outcomes in patients with chronic kidney disease, even if they don’t have anemia.

In a recent review, researchers describe what is currently known about allogenic hemopoietic stem cell transplant (HSCT) for myelofibrosis.

Posters presented at the European Hematology Association 2021 Virtual Congress evaluated acute myeloid leukemia (AML) in elderly patients.

A long-term Swedish study found that nonalcoholic fatty liver disease (NALFD) significantly increased mortality in children and young adults, particularly due to cancer, cardiometabolic disease, and liver disease.

Data from IMpower 130, IMpower 132, and IMpower 150 confirm that combining atezolizumab with chemotherapy is the best first-line treatment in advanced NSCLC when anti-PD-L1 therapy is indicated.

A retrospective analysis of real-world data found a discrepancy between actual care and the recommendations from clinical trials for patients with mantle cell lymphoma, resulting in outcomes that were worse than in trials.

The findings, say the researchers, highlight a need for prognostic models specific to patients with prefibrotic primary myelofibrosis (pre-PMF).

Years of research has shown that in cancers like melanoma, liquid biopsy enables the detection of biomarkers, such as circulating tumor cells, circulating tumor DNA, and exomes.

Manipulating the expression of MAGEA3 can help block the growth of hepatocellular carcinoma.

Topical and intravenous tranexamic acid (TXA) were found to significantly reduce blood loss compared with placebo in patients who have undergone bone surgery, suggesting that both administration methods may be effective at promoting wound healing.

A recent study examined the prevalence and characteristics of 3 atypical pathogens responsible for respiratory tract infections in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), as well as evaluated optimal detection methods.

The National Comprehensive Cancer Network (NCCN) has updated its guidelines for Waldenström macroglobulinemia to include zanubrutinib (Brukinsa) as a preferred regimen.

Based on the prognostic value observed in the study, the researchers suggest that evaluating circulating tumor DNA (ctDNA) status as early as within a week of surgery could aid in risk stratification of patients and decision-making for postoperative management.

The study included over 900 patients with hematologic cancers who were hospitalized with COVID-19, revealing that giving patients plasma from people who have recovered from the virus improved the rate of 30-day mortality.

The company, uniQure, said it is the largest group of patients with hemophilia B to receive a single gene therapy investigational product so far. 

Minimal residual disease, overall response rate, complete response rate, and stringent complete response may be useful as surrogate end points to estimate progression-free survival (PFS) benefit for patients with newly diagnosed multiple myeloma.

A recent study said superior laryngeal nerve (SLN) blocks are effective for treating neurogenic cough, which are coughs that continue and persist after other conditions are ruled out.

Both sets of data were unveiled at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which was held earlier this month in a virtual format.

New research presented at the 2021 American Society of Clinical Oncology Annual Meeting is painting a clearer picture of what drives differences in mortality and outcomes for patients with prostate cancer. Black men with prostate cancer have higher incidence of both.

Presented as an abstract at the European Hematology Association 2021 Virtual Congress, the study results showed the novel combination resulted in early disease modification among 34 patients.

Two posters presented at the European Hematology Association 2021 Virtual Congress evaluated tyrosine kinase inhibitor (TKI) selection in the front line and compared first-generation to second-generation TKIs.

Favorable genetic characteristics may be able to predict which patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who were treated with venetoclax-rituximab will attain undetectable minimal residual disease (MRD).

Three biologics appeared to increase herpes zoster risk, but 2 other therapies were shown to lower the risk, according to a study of patients in a Taiwanese national database.

Real-world data confirmed the clinical effectiveness of Celltrion Healthcare’s rituximab biosimilar (Truxima, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL).

Previous research has suggested the efficacy of chimeric antigen receptor natural killer (CAR-NK) cells in hematological malignancies, and more recently, preclinical findings have raised the question of whether the type of treatment could be a viable, potentially more attractive option for solid tumors.

New studies into chimeric antigen receptor (CAR)–engineered natural killer (NK) cells has shown promising results, explained Ulrike Köhl, PhD, MD, professor of immune oncology and director of the Institute for Clinical Immunology at the University of Leipzig in Germany.

Ibrutinib is currently a standard of care in relapsed/refractory chronic lymphocytic leukemia, but zanubrutinib is an effective second-line and second-generation option, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds.